TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16446183
Drug: Fondaparinux administered
Normalized name: Fondaparinux
DrugBank: Fondaparinux (DB00569)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fondaparinux administered the morning after surgery
Study: 12946548
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 microg BID via single-dose dry powder inhaler plus on‐demand salbutamol
Study: 11194599
Drug: 5 mmol
Normalized name: dibasic potassium phosphate 15 MMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mmol intravenous magnesium
Study: 11194599
Drug: 10 mmol
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mmol intravenous magnesium
Study: 11194599
Drug: 20 mmol
Normalized name: dibasic potassium phosphate 120 MMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mmol intravenous magnesium
Study: 11194599
Drug: 0 mmol
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mmol intravenous magnesium (placebo)
Study: 2999455
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral acyclovir
Study: 29658344
Drug: Oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptives (OCP)
Study: 29658344
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) + Oral contraceptives (OCP)
Study: 27982406
Drug: Phytotherapy (Gan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytotherapy (Gan Mai Da Zao formula, 50 ml)
Study: 24572995
Drug: Prilocaine-lidocaine (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine-lidocaine (PLA) cream applied to the glans penis for 10 min before measurements
Study: 24572995
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied to the glans penis for 10 min before measurements
Study: 22498045
Drug: Morphine (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (routine intravenous narcotics)
Study: 20430594
Drug: Low Lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Lithium levels (<0.6 mmol/L)
Study: 20430594
Drug: Medium Lithium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium Lithium levels (0.6-0.79 mmol/L)
Study: 20430594
Drug: Low Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low Olanzapine doses (<10mg/day)
Study: 20430594
Drug: Higher Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher Olanzapine doses (10-20mg/day)
Study: 16236142
Drug: Intravenous corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous corticosteroid therapy (500 mg intravenous methylprednisolone daily)
Study: 16236142
Drug: Oral corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral corticosteroid therapy (1 mg/kg oral prednisolone daily)
Study: 16236142
Drug: Intravenous corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous corticosteroid therapy
Study: 10207780
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg, Amoxycillin 1.0 g, Metronidazole 400 mg (12 h post-treatment)
Study: 8563457
Drug: Midodrine (alpha-receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine (alpha-receptor agonist)
Study: 1122828
Drug: Vincristine, chlormethine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine, chlormethine, procarbazine and prednisone (protocol H2‐65) for six months, followed by monthly vinblastine injections.
Study: 1122828
Drug: Vincristine, chlormethine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine, chlormethine, procarbazine and prednisone (protocol H2‐65) with reinduction treatment.
Study: 28478481
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ω-3 fatty acids and nano-curcumin
Study: 21275850
Drug: RAC (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAC (7.5 mg over 1 hour)
Study: 21275850
Drug: LEV (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV (3.75 mg over 1 hour)
Study: 21458532
Drug: Cognitive Remediation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Remediation Therapy (CRT), 40 sessions
Study: 15136378
Drug: Budesonide 200
Normalized name: budesonide 200 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 200 microg (400 microg/d) plus Zafirlukast 20 mg bid
Study: 11091168
Drug: Low-dose citrate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose citrate anticoagulation (60 IU heparin/kg body weight as initial bolus; 1:40 ACD‐A: blood as perfusion)
Study: 11091168
Drug: Standard anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulation regimen (20 IU heparin/kg bolus; 1:20 ACD‐A as perfusion)
Study: 9135702
Drug: Pyridostigmine (PD,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (PD, 120 mg, orally)
Study: 3524842
Drug: Nalbuphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (10 mg IV)
Study: 7541310
Drug: Meperidine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (50 mg IV)
Study: 28641022
Drug: Fitnox (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitnox (250 mg capsule as single dose)
Study: 22498110
Drug: GSK573719 once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK573719 once-daily doses (62.5-1000 μg)
Study: 22498110
Drug: GSK573719 twice-daily
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GSK573719 twice-daily doses (62.5-250 μg)
Study: 20054739
Drug: Quercetin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin supplementation (1000 mg x day(‐1))
Study: 12427189
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution administered prior to endotracheal suctioning
Study: 12427189
Drug: Suctioning without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suctioning without saline solution
Study: 10868559
Drug: E2 1
Normalized name: PGE2 10 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 1 mg/NGM 90 microg
Study: 10617250
Drug: E2 1
Normalized name: PGE2 10 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 1 mg/NGM 30 microg
Study: 10617250
Drug: E2 1
Normalized name: PGE2 10 MG Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 1 mg
Study: 2233115
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg three times daily
Study: 26858331
Drug: High-Dose Interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Interferon Alfa-2b (HDI)
Study: 31299242
Drug: Intensity modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity modulated radiation therapy
Study: 31299242
Drug: 3-dimensional chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-dimensional chemoradiation therapy
Study: 25829048
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (40 mg.kg(‐1))
Study: 24043677
Drug: 23 to
Normalized name: vehicle base no.23 TOPICAL CREAM (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 to 32 mm Hg (moderate) compression stocking treatment
Study: 24043677
Drug: 34 to
Normalized name: cream base no.134 TOPICAL CREAM (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 34 to 46 mm Hg (high) compression stocking treatment
Study: 21642014
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg subcutaneously at weeks 0, 2, and 4
Study: 19806184
Drug: 3 dose
Normalized name: Hep A, ped/adol, 3 dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 dose schedules
Study: 19806184
Drug: RTS,S/AS01(E) and
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTS,S/AS01(E) and rabies vaccine
Study: 15067028
Drug: FU-based therapy
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU-based therapy
Study: 11742269
Drug: Nasal Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal Steroid (NS) - budesonide 400 microg daily
Study: 9338418
Drug: Haloperidol (Seranace,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (Seranace, 0.05 mg/kg)
Study: 7509325
Drug: Cilazapril 2.5-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 2.5-5 mg once daily
Study: 7509325
Drug: Hydrochlorothiazide 25-50
Normalized name: captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25-50 mg once daily
Study: 20962899
Drug: Amiloride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (10 mg)
Study: 18947475
Drug: Rhu‐EPO treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhu‐EPO treatment (250 IU/kg, 3 times weekly for 4 weeks)
Study: 18947475
Drug: Rhu‐EPO treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhu‐EPO treatment
Study: 15714171
Drug: Low-dose tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tacrolimus (0.075 mg/kg/day)
Study: 15714171
Drug: High-dose tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tacrolimus (0.15 mg/kg/day)
Study: 1290620
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg, 100 mg, 150 mg
Study: 1290620
Drug: Losartan 10
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 10 mg, 25 mg
Study: 1290620
Drug: Losartan (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (various doses)
Study: 30860000
Drug: Amphetamine extended-release
Normalized name: amphetamine Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine extended-release oral suspension (AMPH EROS)
Study: 26198386
Drug: 5-week group-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-week group-based multidisciplinary programme of task-oriented exercises integrated with cognitive behavioural therapy
Study: 24460589
Drug: Acidulated phosphate
Normalized name: Acidulated Phosphate Fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidulated phosphate fluoride gel
Study: 24460589
Drug: Antibacterial bonding
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial bonding agent (Clearfil Protect Bond)
Study: 9459240
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of propofol (n = 17)
Study: 9459240
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL of placebo (n = 12)
Study: 2561144
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg benazepril orally once a day for 2 days
Study: 30183398
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (VC) supplementation 300 mg per day for 6 months
Study: 26062187
Drug: Captopril tablets
Normalized name: Captopril Tablets
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril tablets (12.5 mg, twice a day)
Study: 26062187
Drug: Captopril tablets
Normalized name: Captopril Tablets
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril tablets
Study: 21601287
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Bupropion + Escitalopram or Venlafaxine + Mirtazapine)
Study: 21601287
Drug: Monotherapy (Escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (Escitalopram + placebo)
Study: 14706487
Drug: Methylphenidate (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (extended-release version)
Study: 11990444
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EMD and BDX
Study: 9650731
Drug: Allithiamin and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allithiamin and pantethine supplementation (1 g of allithiamin and 1.8 g of a 55%/45% pantethine/pantothenic acid compound)
Study: 7573298
Drug: 0.05 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/day estradiol patch
Study: 7573298
Drug: 0.1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/day estradiol patch
Study: 7663539
Drug: 0.625 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/day oral conjugated estrogens (Premarin)
Study: 2486587
Drug: Warm intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm intravenous crystalloid and prep solutions, extra body covering (Group 2)
Study: 2486587
Drug: No warm
Approvals — FDA: no, EMA: no, PMDA: no
Description: No warm intravenous crystalloid or extra body covering (Group 1)
Study: 31625262
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) with contemporary drug-eluting stents (DES)
Study: 28826895
Drug: Preoperative β-blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative β-blocker use
Study: 23507424
Drug: Atorvastatin 10mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 10mg daily for four weeks
Study: 23507424
Drug: Atorvastatin 40mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 40mg for four weeks
Study: 23507424
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atorvastatin 40mg / ezetimibe 10mg for four weeks
Study: 23507424
Drug: Atorvastatin 40mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 40MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 40mg alone
Study: 28681986
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg)
Study: 21325466
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg)
Study: 15482765
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metformin and rosiglitazone
Study: 11737418
Drug: Transdermal DHT
Normalized name: stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal DHT and one subdermal LNG implant
Study: 11737418
Drug: Transdermal DHT
Normalized name: stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal DHT and two subdermal LNG implants
Study: 11737418
Drug: Transdermal DHT
Normalized name: stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal DHT and four subdermal LNG implants
Study: 11737418
Drug: Transdermal DHT
Normalized name: stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal DHT and oral LNG
Study: 11737418
Drug: Transdermal DHT
Normalized name: stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal DHT only
Study: 9050428
Drug: Group cognitive-behavioral
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive-behavioral treatment of anxiety
Study: 7937352
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion (4 pmol.kg‐1.min‐1)
Study: 31969108
Drug: Remote model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote model intervention with at-home, parent-delivered intervention and weekly video conferencing with interventionists.
Study: 29878280
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of L-DOPA
Study: 28973211
Drug: IVIg (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (0.5 g/kg of body weight)
Study: 28973211
Drug: IVIg (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (2 infusions) in open extension
Study: 16441945
Drug: 600 g
Normalized name: PETROLATUM 600 g in 1000 g TOPICAL OINTMENT [EltaMD Laser Balm]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 g fruit and vegetables/day
Study: 12829681
Drug: Primary systemic
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary systemic therapy (PST)
Study: 10623700
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m(2))
Study: 10623700
Drug: Paclitaxel (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (200 mg/m(2) 24-hour infusion)
Study: 10623700
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of paclitaxel (135 mg/m(2)) followed by cisplatin (75 mg/m(2))
Study: 1489290
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg + Dipyridamole 300 mg
Study: 2418296
Drug: Nicorandil (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (60 mg s.l.)
Study: 2418296
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN; 20 mg s.l.)
Study: 2418296
Drug: Dihydralazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (10 mg i.v.)
Study: 31455312
Drug: Hand therapy
Normalized name: Octinoxate 3.00 mL in 75 mL / Avobenzone 1.5 mL in 75 mL TOPICAL CREAM [Botanics Daily Hand Therapy Sunscreen SPF 10]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand therapy (includes oedema and scar management, splinting, movement exercises, and practice of everyday activities)
Study: 29065098
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium nitrite (NaNO2) infusion at 240 μg/kg/h for 2 hours
Study: 27739087
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline infusion
Study: 27880811
Drug: Domperidone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (0.5 mg/kg)
Study: 25092547
Drug: 8 mg/day
Normalized name: Neupro 8 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/day dexamethasone for 28 days followed by a 2-week taper (enhanced)
Study: 25092547
Drug: 6 mg/day
Normalized name: EMSAM 6 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/day dexamethasone for 10 days (conventional)
Study: 20724711
Drug: Normothermia (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermia (standard treatment)
Study: 7710563
Drug: Diltiazem (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (180 to 360 mg/day)
Study: 2278366
Drug: APA (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: APA (acute parenteral alimentation)
Study: 2278366
Drug: Control (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.9% NaCl solution)
Study: 364003
Drug: 1% Chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Chlorhexidine gel
Study: 21323176
Drug: DTPa-IPV/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-IPV/Hib vaccine
Study: 21323176
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of DTPa-IPV/Hib
Study: 14531817
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low protein diet (VLPD) group (0.3 g/kg body weight/day)
Study: 14531817
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (LPD) group (0.6 g/kg body weight/day)
Study: 9390977
Drug: 1 G
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 G
Study: 9390977
Drug: Approximately 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 1.6 G
Study: 9390977
Drug: 1 G
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 G and approximately 1.6 G
Study: 8150902
Drug: Subcutaneous goserelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous goserelin (3.6 mg)
Study: 8150902
Drug: Intranasal buserelin
Normalized name: buserelin
DrugBank: Buserelin (DB06719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal buserelin acetate (200 micrograms; 6 times/day)
Study: 30294848
Drug: Gastrografin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrografin (100 mL administered through nasointestinal tube once daily for six consecutive days)
Study: 30294848
Drug: Enemas (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enemas (administered once daily for six consecutive days)
Study: 24660675
Drug: Weekly dynamic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dynamic psychotherapy with relationship work
Study: 24660675
Drug: Weekly dynamic
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly dynamic psychotherapy without relationship work
Study: 22113935
Drug: Screening tool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening tool for osteoporotic vertebral fractures (VFs) administered by a nurse in primary care.
Study: 19107626
Drug: Polydextrose (PDX)
Normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polydextrose (PDX) supplementation (8 g/day)
Study: 17443036
Drug: NSAID-ET (NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID-ET (NSAID plus etizolam 0.5 mg)
Study: 17443036
Drug: NSAID (mefenamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID (mefenamic acid 250 mg)
Study: 16046372
Drug: CCK‐4 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCK‐4 injection
Study: 12032191
Drug: Irbesartan 300
Normalized name: irbesartan 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 300 mg o.d.